v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenue $ 11,704,565 $ 9,652,234 $ 21,817,853 $ 19,484,048
Cost of revenue 3,262,017 3,600,061 6,473,698 6,822,246
Gross profit 8,442,548 6,052,173 15,344,155 12,661,802
Operating expenses:        
Research and development 1,720,463 2,001,331 3,343,623 3,791,355
Selling, clinical and marketing 5,264,090 5,233,885 10,080,849 9,629,689
General and administrative 3,712,481 3,407,277 7,331,221 7,351,332
Total operating expenses 10,697,034 10,642,493 20,755,693 20,772,376
Loss from operations (2,254,486) (4,590,320) (5,411,538) (8,110,574)
Other expense (income), net        
Interest expense (income), net 535,744 (106,549) 1,040,440 (298,540)
Change in fair value of derivatives liabilities 1,199,726 0 360,662 0
Total Other (income), net 1,735,470 (106,549) 1,401,102 (298,540)
Loss before income taxes (3,989,956) (4,483,771) (6,812,640) (7,812,034)
Income Tax Expense 31,404 148,201 218,119 284,996
Net loss $ (4,021,360) $ (4,631,972) $ (7,030,759) $ (8,097,030)
Weighted average number of common shares outstanding:        
Basic 42,697,319 41,582,737 42,484,409 41,518,959
Diluted 42,697,319 41,582,737 42,484,409 41,518,959
Net loss per share attributable to common stockholders        
Basic $ (0.09) $ (0.11) $ (0.17) $ (0.2)
Diluted $ (0.09) $ (0.11) $ (0.17) $ (0.2)